

GLAND PHARMA LIMITED

July 4, 2022

BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers 25th floor, Dalal Street Mumbai - 400 001 Scrip Code: 543245

National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor Plot no. C-1, Block G, Bandra Kurla Complex Bandra (East), Mumbai - 400 051 Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as 'Listing Regulations')

This is to inform you that a meeting of the Board of Directors of Gland Pharma Limited ('the Company') will be held on Wednesday, 20th July, 2022, inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2022.

Trading Window:

In continuation to our earlier intimation dated June 30, 2022; this is to inform you that the trading window, which was closed from Friday, 1st July, 2022 in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended; will reopen on Saturday, 23rd July, 2022.

Earnings Call:

The Company will hold an Investor/Analyst call on Wednesday, 20th July, 2022 to discuss the financial results and business outlook. Details of the call will be intimated to the stock exchanges and published on the Company's website (www.glandpharma.com) in due course.

This is for your information and records.

Yours truly,

For Gland Pharma Limited

Sampath Kumar Pallerlamudi

Company Secretary and Compliance Officer